---
title: "Apeloa Pharmaceutical Co., Ltd. (000739.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000739.SZ.md"
symbol: "000739.SZ"
name: "Apeloa Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:00:41.722Z"
locales:
  - [en](https://longbridge.com/en/quote/000739.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000739.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000739.SZ.md)
---

# Apeloa Pharmaceutical Co., Ltd. (000739.SZ)

## Company Overview

Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People’s Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug projects, commercial veterinary drug projects and other commercial projects; pharmaceutical business includes anti-infective, cardiovascular, psychotropic, hepatobiliary and anti-tumor categories. The company also provides technology platforms, such as flow chemistry, synthetic biology and biocatalysis, crystallization and particle engineering, peptide, high potency compound, conjugate library service, oligonucleotide synthesis, and preparation and purification; and controlled-release formulation development, taste masking technology, and particle flow simulation.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.apeloa.com](https://www.apeloa.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 82 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -17.77% |  |
| Net Profit YoY | -13.98% |  |
| P/B Ratio | 2.90 |  |
| Dividend Ratio | 5.69% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 19032267338.01 |  |
| Revenue | 9517721898.78 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.15% | B |
| Profit Margin | 9.38% | B |
| Gross Margin | 29.30% | C |
| Revenue YoY | -17.77% | E |
| Net Profit YoY | -13.98% | D |
| Total Assets YoY | -3.61% | D |
| Net Assets YoY | -6.13% | D |
| Cash Flow Margin | 152.63% | B |
| OCF YoY | -17.77% | E |
| Turnover | 0.76 | B |
| Gearing Ratio | 46.37% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Apeloa Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-17.77%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.90",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "5.69%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "19032267338.01",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9517721898.78",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.15%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.38%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "29.30%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-17.77%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-13.98%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.61%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.13%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "152.63%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-17.77%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.76",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "46.37%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.32 | 52/215 | 23.75 | 21.07 | 17.95 |
| PB | 2.90 | 135/215 | 3.23 | 2.88 | 2.72 |
| PS (TTM) | 2.00 | 32/215 | 2.03 | 1.75 | 1.61 |
| Dividend Yield | 5.69% | 6/215 | 4.36% | 3.92% | 2.43% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-21T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Overweight | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.82 |
| Highest Target | 21.00 |
| Lowest Target | 19.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000739.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000739.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000739.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000739.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**